

- Alternative splicing, 444e-1
 Alternative systems of medicine, 14e-1. *See also* Complementary and alternative medicine
 Altitude illness. *See* High-altitude illness
 Altretamine, 103e-9t, 103e-12
 Aluminum hydroxide, 1920
 Aluminum toxicity
 erythropoietin therapy response and, 631
 etiology of, 320
 hypercalcemia due to, 2479
 neurologic, 472e-3, 2608
 pulmonary, 1691
 Alveolar collapse, 1738
 Alveolar flooding, 1731
 Alveolar gas equation, 306e-3
 Alveolar hemorrhage, diffuse, 245
 Alveolar hypoventilation, 1732
 Alveolar proteinosis, primary, 375e-2
 Alvimopan, 92
 Alzheimer's disease (AD), **2598**
 aluminum and, 472e-3
 clinical features of, 172, **2598**
 aphasia, 178, 179–180
 Bálint's syndrome, 182
 depression, 2714
 frontal lobe syndromes, 184
 involuntary weight loss, 275
 memory loss, 183
 olfactory dysfunction, 211, 215
 deaths from, 6e-1t, 56t
 dementia with Lewy bodies and, 2606. *See also* Dementia with Lewy bodies
 differential diagnosis of, 171t, 2599
 in Down's syndrome, 2600–2601
 epidemiology of, 2599
 familial, 2600–2601
 functional anatomy of, 170
 genetic considerations in, 444e-9, 2600–2601
 imaging in, 174f, 175f, 2599
 incidence of, 2598
 pathology of, 172t, 2599–2600, 2600f
 pathophysiology of
 A β peptide, 453e-6, 719
 amyloid plaques, 76, 444e-9
 genetic factors, 172t, 448
 molecular, 172t
 prions, 444e-8f, 444e-10, 453e-1, 453e-6
 signaling pathways, 444e-4
 PD and, 2599
 presenilins in, 2601
 treatment of, 176, 2601–2602
 with and without other dementia, 94e-1
 in women, 6e-1–2, 6e-2f
 AMA (antimitochondrial antibodies), 2060
 Amalgam tattoo, 240t
 AMAN (acute motor axonal neuropathy), 2695, 2695t, 2696t
 Amanita mushrooms, 267, 283, 473e-9t
 Amantadine
 action of, 214e-9, 215e-5–6
 adverse effects of, 215e-6, 1213–1214, 2616
 for fatigue in MS, 2672
 for influenza prophylaxis, 215e-2t, 215e-5, 1213t, 1214, 1252t
 for influenza treatment, 215e-2t, 1213–1214, 1213t
 overdosage/poisoning with, 473e-8t, 473e-13t
 for PD, 2616, 2618
 pharmacology of, 215e-5
 resistance to, 215e-2t, 215e-5
 for SSRI-related sexual dysfunction, 2716
 Amaurosis, congenital. *See* Leber's hereditary optic neuropathy (congenital amaurosis)
 Amaurosis fugax, 40e-4, 200–202, 2574
 Amblyomma spp. ticks, 1152, 1154. *See also* Tick-borne diseases
 Amblyopia, 208
 Ambrisentan, 1660, 1660t
 Ameba, free-living. *See* *Acanthamoeba*; *Balamuthia*; *Naegleria*
metabolism of, disorders of, 434e-1, 434e-2–3t
renal transport of, 332e-3f, 332e-8
in specialized nutritional support formulas, 98e-5
types of, 434e-1
 Aminoaciduria(s), 435e-1t, 435e-2
 Aminoacyl-tRNA histidyl synthetase, 372e-24t
 Aminoacyl-tRNA synthetase, 372e-24t
 Aminobenzoic acid esters, 389t
 ϵ -Aminocaproic acid
 adverse effects of, 309, 2199
 for CIINH deficiency, 2120
 for DIC, 738
 for hemophilia, 734
 for thrombocytosis, 678
 for von Willebrand disease, 731–732
 Aminoglutethimide, 103e-16, 2273
 Aminoglycosides
 action of, 930, 931t, 932f, 942
 adverse effects of, 938t
 hearing loss, 219
 hypokalemia, 306
 in myasthenia gravis, 2703
 nephrotoxicity, 1803
 for anaerobic bacterial infections, 1101t
 for cystic fibrosis, 1699
 for enterococcal infections, 974, 975t
 indications for, 942
 for infections in cancer patient, 491
 for infective endocarditis, 821
 for osteomyelitis, 840t
 for postpartum endomyometritis, 50
 resistance to, 821, 931t, 934, 976, 1118
 for tuberculosis, 205e-2t
 5-Aminolevulinic acid (ALA), 386
 5-Aminolevulinic acid (ALA) dehydrase, 2523t, 2524
 5-Aminolevulinic acid (ALA)-dehydratase deficient porphyria, 2521, 2522f, 2522t, 2523t, **2526**
 5-Aminolevulinic acid (ALA) synthase, 2522, 2523t, 2524–2525
 Aminophylline, 254, 324, 1677, 1679, 2117
 4-Aminopyridine, 2672
 Aminosalicilic acid, 727t
 Aminosidine. *See* Paromomycin
 Aminotransferase(s), 283, 1997, 1998t
 Amiodarone
 action of, 273e-6t
 adverse effects of
 in chronic lung disease, 36
 cutaneous, 361, 379
 hepatotoxicity, 2025, 2029
 hyperthyroxinemia, 2286t
 interstitial lung disease, 1714
 myopathy, 462e-20, 462e-20t, 2199, 2218t
 neuropathy, 2687t, 2688
 nonarrhythmic, 1480t, 1499
 optic neuropathy, 203
 phototoxicity, 389t
 proarrhythmic, 1480t, 1499
 secondary parkinsonism, 2611
 thrombocytopenia, 727t
 thyrotoxicosis, 2300
 for arrhythmias, 1479t, 1480t
 for atrial fibrillation, 1489
 for cardiac arrest, 1769f, 1770
 dosage of, 1479t, 1480t
 drug interactions of
 calcium channel blockers, 34t
 digoxin, 42t
 protease inhibitors, 34t
 quinidine, 42t, 246e-6t
 statins, 2199
 warfarin, 34t, 42t
 ECG changes caused by, 1458f
 for focal atrial tachycardia, 1479
 monitoring during treatment with, 1499
 for multifocal atrial tachycardia, 1485
 pharmacology of, 1480t
 thyroid function and, 2300
 for ventricular arrhythmias, 1494, 1495, 1498–1499